Amit G. Pandya

Amit G. Pandya

Dermatology

401 Old San Francisco Road
Level 2
Sunnyvale, CA 94086

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.

Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.

Journal: JAMA dermatology

Published: May 06, 2026

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

Journal: JAMA dermatology

Published: March 25, 2026

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Journal: Advances in therapy

Published: March 11, 2026

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Journal: Lancet (London, England)

Published: February 27, 2026

Assessment of vitiligo in clinical practice: a cross-sectional survey among experts.

Assessment of vitiligo in clinical practice: a cross-sectional survey among experts.

Journal: The Journal of dermatological treatment

Published: October 10, 2025

Combining Thyroid Imaging Report and Data System (TIRADS) and Afirma Genomic Sequencing Classifier (GSC) for potential improvement of malignant risk stratification of Bethesda III thyroid nodules.

Combining Thyroid Imaging Report and Data System (TIRADS) and Afirma Genomic Sequencing Classifier (GSC) for potential improvement of malignant risk stratification of Bethesda III thyroid nodules.

Journal: Journal of the American Society of Cytopathology

Published: September 17, 2025

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.

Journal: Dermatology and therapy

Published: August 04, 2025

Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo.

Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo.

Journal: The Journal of investigative dermatology

Published: July 21, 2025

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Journal: The British journal of dermatology

Published: June 25, 2025

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

Journal: The British journal of dermatology

Published: June 25, 2025

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.

Journal: The British journal of dermatology

Published: June 13, 2025

Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655].

Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655].

Journal: EClinicalMedicine

Published: April 07, 2025

Showing 1-12 of 158

Last Updated: 09/26/2026